• BIRB 796 (Doramapimod): Precision p38α MAPK Inhibitor Workfl

  2026-07-17

  BIRB 796 (Doramapimod) stands out as a highly selective and dual-action p38α MAPK inhibitor, enabling advanced inflammation research and apoptosis assays. Recent structural and mechanistic insights support refined protocols for cytokine modulation and kinase dephosphorylation, driving experimental reproducibility and specificity.

• Annexin V-FITC/PI Apoptosis Assay Kit: Innovations in Retina

  2026-07-17

  Explore how the Annexin V-FITC/PI Apoptosis Assay Kit enables advanced, high-resolution detection of apoptosis, with a unique focus on photoreceptor protection and translational retinal research. This in-depth analysis highlights new scientific findings and practical assay strategies for biomedical innovation.

• Gli1+ Progenitors Drive Glucocorticoid-Induced Osteoporosis

  2026-07-16

  This study identifies Gli1+ metaphyseal mesenchymal progenitors as key mediators of glucocorticoid-induced osteoporosis in vivo, revealing that glucocorticoids impair both the proliferation and differentiation of these osteogenic cells. The findings provide a focused mechanistic target for therapeutic intervention and refine our understanding of bone loss under glucocorticoid therapy.

• Sulfachloropyridazine Alters Cecal Microbiota in E. tenella

  2026-07-16

  This study investigates how sulfachlorpyridazine, ethanamizuril, and their combination influence the cecal microbiota and metabolic profiles in chickens infected with Eimeria tenella. The findings offer mechanistic insight into the modulation of gut microbial and metabolic responses by these treatments, with implications for optimizing anticoccidial and antimicrobial research models.

• GM 6001 (Galardin): Strategic Leverage in Translational MMP

  2026-07-15

  Discover how GM 6001 (Galardin) enables translational researchers to precisely dissect matrix metalloproteinase (MMP) biology, overcome experimental bottlenecks in meniscal healing and cancer studies, and strategically bridge mechanistic insights with emerging combination therapies. This article integrates mechanistic rationale, experimental best practices, and the evolving landscape of MMP-targeted interventions, while critically referencing breakthrough studies and offering actionable protocol guidance.

• 10074-G5: Unlocking c-Myc Inhibition for Precision Cancer Mo

  2026-07-15

  Explore the unique capabilities of 10074-G5 as a c-Myc inhibitor, with in-depth analysis of its mechanistic action and advanced applications in translational cancer research. This article provides protocol insights and positions 10074-G5 as an essential tool for apoptosis and tumor regression studies.

• Amiloride (MK-870) in Sodium Channel & Endocytosis Research

  2026-07-14

  Amiloride (MK-870) stands out as a dual-action inhibitor, enabling precise dissection of sodium channel activity and endocytic pathways in cellular models. This article unpacks advanced experimental workflows, evidence-based troubleshooting, and comparative insights—empowering researchers to push the boundaries of ion transport and receptor signaling studies.

• Dissecting the CaN/FoxO1/FABP4 Pathway in Atherosclerosis Pr

  2026-07-14

  This study elucidates how SERCA2 dysfunction accelerates atherosclerosis through the calcineurin/FoxO1/FABP4 pathway, driving foam cell formation in macrophages. Targeting this axis, particularly via FABP4 inhibition, emerges as a promising strategy for correcting aberrant lipid metabolism and mitigating atherosclerotic lesion development.

• Dimethyloxalylglycine (DMOG): Technical Guidance for Hypoxia

  2026-07-13

  Dimethyloxalylglycine (DMOG) is a cell-permeable, competitive inhibitor of prolyl-4-hydroxylase domain enzymes, providing a practical tool for stabilizing hypoxia-inducible factor (HIF) in vitro and in vivo. It is best suited for controlled studies of oxygen sensing, hypoxia signaling, and inflammation models, but should not be used in diagnostic or therapeutic applications.

• CDC42 Regulates HBV Entry via NTCP Trafficking and Macropino

  2026-07-13

  This study elucidates how CDC42 facilitates hepatitis B virus (HBV) entry into hepatocytes by promoting NTCP translocation to the plasma membrane and enabling CDC42-dependent macropinocytosis. The findings highlight novel host-pathogen interactions and identify CDC42 signaling as a potential target for antiviral strategies.

• AMG 9810: Optimizing TRPV1 Antagonist Assays for Sensory Neu

  2026-07-12

  AMG 9810 is a nanomolar TRPV1 antagonist that enables precise inhibition of sensory neuron signaling in pain mechanism research. This article delivers advanced workflow guidance, practical troubleshooting, and insight into integrating metabolic stress findings for robust assay design.

• Simvastatin (Zocor): Mechanism, Benchmarks, and Research Use

  2026-07-10

  Simvastatin (Zocor) is a potent cholesterol synthesis inhibitor and apoptosis inducer in hepatic cancer cell models. Its validated action on HMG-CoA reductase underpins its utility in hyperlipidemia and cancer research. This article details its biochemical mechanism, evidentiary benchmarks, and integration into experimental workflows.

• Annexin V-FITC/PI Apoptosis Assay Kit: Practical Guidelines

  2026-07-09

  The Annexin V-FITC/PI Apoptosis Assay Kit enables rapid and reliable detection of apoptosis stages in cultured cells using flow cytometry or fluorescence microscopy. It is optimized for research workflows that require clear discrimination between viable, early apoptotic, and late apoptotic or necrotic cells. This kit should not be used for diagnostic or clinical decision-making.

• Azathramycin A: Macrolide Antibiotic for Tuberculosis Resear

  2026-07-09

  Azathramycin A is a macrolide antibiotic that inhibits Mycobacterium tuberculosis ribosomes and is mainly used as an antibacterial agent in tuberculosis research. Its well-defined mechanism and origin as a degradation product of azithromycin enable precise study of protein synthesis inhibition and antibiotic resistance. This article outlines its biological rationale, validated mechanism, and key protocol considerations.

• iRhom2 Regulates Olfactory Receptor Adaptation via ADAM17

  2026-07-08

  Azzopardi et al. reveal that iRhom2, previously understudied in the nervous system, is uniquely expressed in mouse olfactory sensory neurons and regulates olfactory receptor (OR) gene expression and activity-dependent adaptation via ADAM17 signaling. This discovery refines our understanding of olfactory plasticity and provides a framework for dissecting GPCR-mediated feedback in sensory systems.

16289 records 1/1086 page Next 12345 下5页 Last page